Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil

Authors

Brett J. Loechelt, George Washington University
David Boulware, University of South Florida
Michael Green, Children's Hospital of Pittsburgh
Lindsey R. Baden, Brigham and Women's Hospital, Boston, MA
Peter Gottlieb, University of Colorado Denver
Heidi Krause-Steinrauf, George Washington University
Adriana Weinberg, University of Colorado DenverFollow

Document Type

Journal Article

Publication Date

1-15-2013

Journal

Clinical Infectious Diseases

Volume

Volume 56, Issue 2

Inclusive Pages

248-254

Keywords

Antibodies; Monoclonal; Humanized--adverse effects; Diabetes Mellitus; Type 1--complications; Epstein-Barr Virus Infections--etiology; Herpesviridae Infections--etiology; Immunoglobulin G--adverse effects; Immunosuppressive Agents--adverse effects; Mycophenolic Acid--analogs & derivatives

Comments

This is a PubMed Central article. Click on link for full-text access.

APA Citation

Loechelt, B. J., Boulware, D., Green, M., Baden, L. R., Gottlieb, P., Krause-Steinrauf, H., & Weinberg, A. (2013). Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clinical Infectious Diseases, 56(2), 248-254.

Peer Reviewed

1

Open Access

1